benzonatate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
326 104-31-4

Description:

MoleculeDescription

Synonyms:

  • tessalon
  • benzonatate
  • benzononantin
  • benzononatine
  • Molecular weight:
  • Formula: C12H17NO2(C2H4O)7-9
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
0.60 g O

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 14.20 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Hosey CM, Chan R, Benet LZ
S (Water solubility) 0.00 mg/mL Bocci G, Oprea TI, Benet LZ

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
Feb. 10, 1958 FDA PFIZER

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pneumonia 179.21 13.33 463 23162 637596 89967226
Bronchitis 148.60 13.33 191 23434 152736 90452086
Cough 144.11 13.33 305 23320 368657 90236165
Completed suicide 126.75 13.33 172 23453 144886 90459936
COVID-19 119.35 13.33 181 23444 168662 90436160
Product dose omission issue 110.17 13.33 238 23387 291449 90313373
Upper respiratory tract infection 85.63 13.33 134 23491 128184 90476638
Cardiac arrest 79.11 13.33 116 23509 104819 90500003
Asthma 78.44 13.33 186 23439 241974 90362848
Maternal exposure during pregnancy 77.41 13.33 4 23621 360059 90244763
Influenza 72.32 13.33 130 23495 139134 90465688
Synovitis 69.83 13.33 4 23621 329748 90275074
Dyspnoea 69.59 13.33 429 23196 880526 89724296
Contraindicated product administered 67.44 13.33 4 23621 320135 90284687
Glossodynia 62.18 13.33 6 23619 321773 90283049
Systemic lupus erythematosus 62.05 13.33 10 23615 361886 90242936
Death 61.83 13.33 259 23366 456292 90148530
Impaired quality of life 61.81 13.33 50 23575 23094 90581728
Electrocardiogram change 58.16 13.33 17 23608 777 90604045
Illness 56.61 13.33 87 23538 81882 90522940
Pericarditis 55.04 13.33 4 23621 270147 90334675
Treatment failure 52.99 13.33 8 23617 303920 90300902
Wound 52.77 13.33 8 23617 302972 90301850
Therapy interrupted 52.42 13.33 65 23560 50043 90554779
Chronic obstructive pulmonary disease 51.88 13.33 79 23546 73750 90531072
Infusion related reaction 47.06 13.33 25 23600 416755 90188067
Respiratory arrest 46.25 13.33 50 23575 33261 90571561
Conduction disorder 45.11 13.33 17 23608 1718 90603104
Hypoxia 44.68 13.33 73 23552 72326 90532496
Hepatic enzyme increased 43.19 13.33 20 23605 360716 90244106
Arthropathy 41.30 13.33 22 23603 366220 90238602
Angiokeratoma 40.80 13.33 9 23616 128 90604694
Joint swelling 40.40 13.33 43 23582 503257 90101565
Drug intolerance 39.68 13.33 35 23590 447556 90157266
Dermatitis atopic 39.38 13.33 39 23586 23433 90581389
Acute respiratory failure 39.12 13.33 52 23573 42866 90561956
Drug ineffective 36.57 13.33 212 23413 1384086 89220736
General physical health deterioration 36.27 13.33 24 23601 355091 90249731
Blister 35.75 13.33 11 23614 254987 90349835
Exposure during pregnancy 33.94 13.33 10 23615 238400 90366422
Therapeutic product effect decreased 33.82 13.33 15 23610 277556 90327266
C-reactive protein increased 33.45 13.33 4 23621 181385 90423437
Hospitalisation 32.69 13.33 90 23535 128010 90476812
Lower respiratory tract infection 31.41 13.33 13 23612 250646 90354176
Toxicity to various agents 31.17 13.33 153 23472 287693 90317129
Seasonal allergy 31.03 13.33 34 23591 22949 90581873
Irritable bowel syndrome 30.84 13.33 8 23617 207440 90397382
Productive cough 30.29 13.33 64 23561 76999 90527823
Impaired healing 29.58 13.33 12 23613 234187 90370635
Inflammation 28.30 13.33 6 23619 178586 90426236
COVID-19 pneumonia 26.49 13.33 28 23597 18149 90586673
White blood cell count decreased 25.08 13.33 98 23527 167011 90437811
Rheumatoid arthritis 24.83 13.33 35 23590 362579 90242243
Liver injury 24.55 13.33 7 23618 170560 90434262
Drug interaction 24.02 13.33 22 23603 276431 90328391
Surgery 23.40 13.33 42 23583 44845 90559977
Pulmonary embolism 23.22 13.33 81 23544 130739 90474083
Viral infection 23.20 13.33 40 23585 41374 90563448
Mobility decreased 22.93 13.33 19 23606 250715 90354107
Back pain 22.73 13.33 151 23474 317024 90287798
Swelling 22.68 13.33 47 23578 419011 90185811
Joint range of motion decreased 22.66 13.33 4 23621 135639 90469183
Respiratory failure 22.49 13.33 75 23550 118343 90486479
Cardio-respiratory arrest 20.94 13.33 49 23576 63091 90541731
Musculoskeletal stiffness 20.92 13.33 28 23597 296504 90308318
Seizure 20.90 13.33 87 23538 152542 90452280
Respiratory tract infection 20.86 13.33 47 23578 59031 90545791
Pulse absent 20.36 13.33 15 23610 6040 90598782
Decerebrate posture 19.86 13.33 5 23620 129 90604693
Urinary tract infection 19.82 13.33 142 23483 305490 90299332
Off label use 19.80 13.33 188 23437 1102064 89502758
Haemoptysis 19.75 13.33 33 23592 33287 90571535
Bursitis 19.71 13.33 5 23620 131649 90473173
Fatigue 18.98 13.33 413 23212 1153610 89451212
Sinus disorder 18.94 13.33 33 23592 34414 90570408
Product dose omission in error 18.92 13.33 25 23600 20478 90584344
Alopecia 18.88 13.33 66 23559 495005 90109817
Nasal congestion 18.75 13.33 56 23569 83358 90521464
Ill-defined disorder 18.19 13.33 13 23612 184878 90419944
Type 2 diabetes mellitus 17.85 13.33 16 23609 203228 90401594
Conjunctival pigmentation 17.52 13.33 4 23621 67 90604755
Fibromyalgia 17.22 13.33 17 23608 206252 90398570
Intentional product misuse 16.35 13.33 56 23569 89548 90515274
Facet joint syndrome 16.22 13.33 3 23622 98386 90506436
Product use issue 16.21 13.33 39 23586 329880 90274942
Wound infection 16.00 13.33 4 23621 106398 90498424
Full blood count decreased 15.75 13.33 28 23597 29661 90575161
Nausea 15.65 13.33 389 23236 1109927 89494895
Deep vein thrombosis 15.63 13.33 56 23569 91564 90513258
Pneumothorax 15.61 13.33 22 23603 19145 90585677
Chills 15.61 13.33 72 23553 131909 90472913
Abdominal discomfort 15.41 13.33 68 23557 477260 90127562
Diarrhoea 15.37 13.33 336 23289 938854 89665968
Hypervolaemia 15.01 13.33 29 23596 32728 90572094
Palmar erythema 14.71 13.33 8 23617 1903 90602919
Fall 14.33 13.33 190 23435 481620 90123202
Hospice care 14.23 13.33 15 23610 9689 90595133
Sleep disorder due to a general medical condition 14.05 13.33 34 23591 44704 90560118
Therapy cessation 14.05 13.33 30 23595 36331 90568491
Therapeutic product effect incomplete 13.98 13.33 18 23607 193878 90410944
Hypersensitivity 13.94 13.33 66 23559 454611 90150211
Osteoporosis 13.82 13.33 4 23621 96527 90508295
Coma 13.78 13.33 46 23579 72586 90532236
Psoriatic arthropathy 13.75 13.33 24 23601 228311 90376511
Electrocardiogram abnormal 13.50 13.33 15 23610 10283 90594539

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pneumonia 135.32 16.07 308 10047 421841 42189139
Death 64.67 16.07 255 10100 470930 42140050
Cough 64.59 16.07 137 10218 177966 42433014
Conduction disorder 53.89 16.07 21 10334 2497 42608483
Bronchitis 45.97 16.07 57 10298 47144 42563836
Intentional product use issue 43.43 16.07 69 10286 71764 42539216
Acute respiratory failure 36.35 16.07 46 10309 38812 42572168
Dyspnoea 31.43 16.07 199 10156 442422 42168558
Product dose omission issue 30.96 16.07 95 10260 154270 42456710
Therapy interrupted 30.35 16.07 32 10323 22218 42588762
Electrocardiogram QT prolonged 30.27 16.07 47 10308 47898 42563082
Fatigue 29.77 16.07 194 10161 435447 42175533
Electrocardiogram QRS complex prolonged 26.69 16.07 17 10338 5806 42605174
Nasopharyngitis 23.06 16.07 58 10297 83938 42527042
Renal tubular injury 21.85 16.07 10 10345 1769 42609211
COVID-19 21.06 16.07 69 10286 115879 42495101
Bundle branch block 20.12 16.07 8 10347 1002 42609978
Hypoxia 20.01 16.07 49 10306 69737 42541243
Drug ineffective 18.91 16.07 84 10271 630113 41980867
Influenza 18.19 16.07 44 10311 62131 42548849
Atrioventricular block first degree 18.15 16.07 14 10341 6477 42604503
Liver function test increased 17.63 16.07 23 10332 19975 42591005
Bundle branch block right 17.43 16.07 15 10340 8091 42602889
Respiratory failure 17.12 16.07 69 10286 128063 42482917
Non-small cell lung cancer 16.76 16.07 12 10343 4962 42606018
Plasma cell myeloma 16.49 16.07 36 10319 47542 42563438
Atrial fibrillation 16.19 16.07 72 10283 139521 42471459
Sarcomatoid carcinoma of the lung 16.14 16.07 3 10352 18 42610962

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pneumonia 235.42 13.36 611 27174 876103 109685411
Bronchitis 133.02 13.36 180 27605 156852 110404662
Cough 126.65 13.36 325 27460 461316 110100198
Completed suicide 115.01 13.36 213 27572 242168 110319346
Death 110.02 13.36 405 27380 698464 109863050
Product dose omission issue 101.35 13.36 239 27546 321543 110239971
Conduction disorder 100.56 13.36 38 27747 4017 110557497
COVID-19 97.55 13.36 200 27585 244860 110316654
Acute respiratory failure 80.62 13.36 97 27688 75163 110486351
Dyspnoea 79.60 13.36 512 27273 1106360 109455154
Influenza 66.05 13.36 137 27648 168964 110392550
Cardiac arrest 65.01 13.36 149 27636 196604 110364910
Hypoxia 62.85 13.36 115 27670 129400 110432114
Upper respiratory tract infection 59.22 13.36 113 27672 131215 110430299
Synovitis 56.54 13.36 3 27782 274089 110287425
Impaired quality of life 50.27 13.36 49 27736 29968 110531546
Electrocardiogram change 49.39 13.36 17 27768 1374 110560140
Asthma 46.97 13.36 154 27631 250137 110311377
Chronic obstructive pulmonary disease 45.64 13.36 91 27694 109067 110452447
Intentional product use issue 45.15 13.36 151 27634 247755 110313759
Contraindicated product administered 44.82 13.36 5 27780 248262 110313252
Toxicity to various agents 43.83 13.36 237 27548 480318 110081196
C-reactive protein increased 43.09 13.36 3 27782 217916 110343598
Treatment failure 42.30 13.36 9 27776 277225 110284289
Pericarditis 40.61 13.36 4 27781 219110 110342404
Drug intolerance 39.31 13.36 27 27758 406485 110155029
Infusion related reaction 38.65 13.36 24 27761 381138 110180376
Drug ineffective 38.36 13.36 225 27560 1520315 109041199
Productive cough 38.21 13.36 87 27698 114218 110447296
Hypervolaemia 37.79 13.36 54 27731 49406 110512108
General physical health deterioration 37.60 13.36 31 27754 425264 110136250
Electrocardiogram QRS complex prolonged 37.56 13.36 29 27756 12992 110548522
Illness 37.39 13.36 71 27714 82100 110479414
Systemic lupus erythematosus 37.31 13.36 9 27776 254329 110307185
Angiokeratoma 37.01 13.36 9 27776 208 110561306
Respiratory arrest 36.50 13.36 58 27727 58241 110503273
Respiratory failure 35.57 13.36 127 27658 215205 110346309
Glossodynia 34.29 13.36 7 27778 221997 110339517
Therapy interrupted 33.18 13.36 51 27734 49771 110511743
Seizure 32.81 13.36 126 27659 221059 110340455
Intentional product misuse 30.72 13.36 88 27697 132816 110428698
Sinus tachycardia 30.27 13.36 46 27739 44447 110517067
Pneumonitis 29.85 13.36 62 27723 76469 110485045
Therapeutic product effect decreased 29.84 13.36 12 27773 244304 110317210
Fatigue 29.77 13.36 449 27336 1215509 109346005
Joint swelling 29.42 13.36 41 27744 442804 110118710
Arthropathy 29.28 13.36 18 27767 287504 110274010
Dermatitis atopic 29.12 13.36 34 27751 25507 110536007
COVID-19 pneumonia 29.04 13.36 41 27744 37102 110524412
Electrocardiogram QT prolonged 29.02 13.36 76 27709 108884 110452630
Nasal congestion 28.72 13.36 71 27714 98211 110463303
Inflammation 28.02 13.36 7 27778 193231 110368283
Lower respiratory tract infection 28.01 13.36 13 27772 243093 110318421
Exposure during pregnancy 26.44 13.36 5 27780 167419 110394095
Pulmonary embolism 26.13 13.36 115 27670 214359 110347155
Hospice care 25.99 13.36 23 27762 12450 110549064
Irritable bowel syndrome 25.73 13.36 5 27780 164210 110397304
Atrioventricular block first degree 25.29 13.36 24 27761 14201 110547313
Off label use 24.99 13.36 249 27536 1499936 109061578
Wound 24.82 13.36 14 27771 234423 110327091
Therapy cessation 24.54 13.36 42 27743 44815 110516699
Atrial fibrillation 22.77 13.36 116 27669 229526 110331988
Hospitalisation 22.63 13.36 83 27702 142410 110419104
Bursitis 22.50 13.36 3 27782 129915 110431599
Blister 22.10 13.36 15 27770 227361 110334153
Urinary tract infection 22.09 13.36 149 27636 326133 110235381
Liver injury 20.77 13.36 6 27779 150407 110411107
Back pain 20.29 13.36 161 27624 370835 110190679
Hepatic enzyme increased 20.04 13.36 31 27754 320861 110240653
Haemoptysis 19.23 13.36 50 27735 71304 110490210
Impaired healing 19.09 13.36 13 27772 196704 110364810
Bundle branch block 18.36 13.36 9 27776 1794 110559720
Pulse absent 18.10 13.36 18 27767 11274 110550240
Rheumatoid arthritis 17.71 13.36 30 27755 299583 110261931
Cardiac failure congestive 17.66 13.36 80 27705 150920 110410594
Swelling 17.42 13.36 39 27746 351002 110210512
Seasonal allergy 17.27 13.36 23 27762 19699 110541815
Decerebrate posture 17.09 13.36 5 27780 238 110561276
Conjunctival pigmentation 17.05 13.36 4 27781 79 110561435
Ear discomfort 16.33 13.36 17 27768 11232 110550282
Renal tubular injury 16.28 13.36 10 27775 3098 110558416
Rhabdomyolysis 16.26 13.36 5 27780 120396 110441118
Sarcomatoid carcinoma of the lung 16.04 13.36 3 27782 18 110561496
Pulmonary arterial hypertension 15.88 13.36 29 27756 32539 110528975
Liver disorder 15.78 13.36 8 27777 142235 110419279
Therapeutic product effect incomplete 15.58 13.36 20 27765 223785 110337729
Non-small cell lung cancer 15.28 13.36 14 27771 7921 110553593
Facet joint syndrome 15.06 13.36 3 27782 96825 110464689
Pleural effusion 15.06 13.36 86 27699 177623 110383891
Full blood count decreased 14.92 13.36 28 27757 32071 110529443
Joint range of motion decreased 14.84 13.36 6 27779 121826 110439688
Deep vein thrombosis 14.81 13.36 72 27713 139815 110421699
Musculoskeletal stiffness 14.78 13.36 30 27755 279792 110281722
Product administration interrupted 14.52 13.36 16 27769 11276 110550238
Myelosuppression 14.51 13.36 3 27782 94337 110467177
Suicide attempt 14.50 13.36 4 27781 103390 110458124
White blood cell count decreased 14.48 13.36 103 27682 229287 110332227
Fibromyalgia 14.42 13.36 13 27772 170896 110390618
Ill-defined disorder 14.39 13.36 11 27774 156842 110404672
Non-cardiac chest pain 14.07 13.36 15 27770 10183 110551331
Rhinovirus infection 13.95 13.36 16 27769 11773 110549741
Mobility decreased 13.82 13.36 24 27761 237398 110324116
Paranasal sinus discomfort 13.72 13.36 12 27773 6393 110555121
Insurance issue 13.58 13.36 15 27770 10597 110550917
Chills 13.47 13.36 88 27697 190492 110371022
Bundle branch block right 13.41 13.36 16 27769 12275 110549239

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC R05DB01 RESPIRATORY SYSTEM
COUGH AND COLD PREPARATIONS
COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS
Other cough suppressants
FDA PE N0000009010 Decreased Tracheobronchial Stretch Receptor Activity
CHEBI has role CHEBI:38867 anaesthetic
CHEBI has role CHEBI:51177 antitussive
MeSH PA D000996 Antitussive Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D019141 Respiratory System Agents
FDA EPC N0000175796 Non-narcotic Antitussive

Related Drugs by ATC class:

R05DB Other cough suppressants 25 drugs
benproperinebibenzoniumbutamirateclobutinolclofedanolcloperastinedibunatedimethoxanatedropropizinedroxypropinefedrilategefapixant show all 25 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Cough indication 49727002




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Sodium channel protein type 5 subunit alpha Ion channel WOMBAT-PK

External reference:

IDSource
D00242 KEGG_DRUG
18993 RXNORM
C0053229 UMLSCUI
CHEBI:3032 CHEBI
CHEMBL1374379 ChEMBL_ID
DB00868 DRUGBANK_ID
C029755 MESH_SUPPLEMENTAL_RECORD_UI
7611 IUPHAR_LIGAND_ID
651 INN_ID
5P4DHS6ENR UNII
7699 PUBCHEM_CID
3024 MMSL
41691 MMSL
4260 MMSL
d00796 MMSL
32760-16-0 SECONDARY_CAS_RN
4018542 VANDF
001663 NDDF
31801005 SNOMEDCT_US
386030001 SNOMEDCT_US
5P4DHS6ENR INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
benzonatate HUMAN PRESCRIPTION DRUG LABEL 1 0440-1185 CAPSULE 100 mg ORAL ANDA 16 sections
Benzonatate HUMAN PRESCRIPTION DRUG LABEL 1 0615-8403 CAPSULE 100 mg ORAL ANDA 16 sections
Benzonatate HUMAN PRESCRIPTION DRUG LABEL 1 0904-6564 CAPSULE 100 mg ORAL ANDA 15 sections
Benzonatate HUMAN PRESCRIPTION DRUG LABEL 1 0904-7153 CAPSULE 100 mg ORAL ANDA 17 sections
Benzonatate HUMAN PRESCRIPTION DRUG LABEL 1 10135-632 CAPSULE 200 mg ORAL ANDA 17 sections
benzonatate HUMAN PRESCRIPTION DRUG LABEL 1 10544-094 CAPSULE 100 mg ORAL ANDA 16 sections
benzonatate HUMAN PRESCRIPTION DRUG LABEL 1 10544-123 CAPSULE 200 mg ORAL ANDA 16 sections
benzonatate HUMAN PRESCRIPTION DRUG LABEL 1 10544-129 CAPSULE 100 mg ORAL ANDA 16 sections
benzonatate HUMAN PRESCRIPTION DRUG LABEL 1 11788-027 CAPSULE 200 mg ORAL ANDA 16 sections
benzonatate HUMAN PRESCRIPTION DRUG LABEL 1 11788-027 CAPSULE 200 mg ORAL ANDA 16 sections
benzonatate HUMAN PRESCRIPTION DRUG LABEL 1 11788-028 CAPSULE 100 mg ORAL ANDA 16 sections
benzonatate HUMAN PRESCRIPTION DRUG LABEL 1 11788-028 CAPSULE 100 mg ORAL ANDA 16 sections
benzonatate HUMAN PRESCRIPTION DRUG LABEL 1 11788-029 CAPSULE 150 mg ORAL ANDA 16 sections
benzonatate HUMAN PRESCRIPTION DRUG LABEL 1 11788-029 CAPSULE 150 mg ORAL ANDA 16 sections
Benzonatate HUMAN PRESCRIPTION DRUG LABEL 1 12634-826 CAPSULE, LIQUID FILLED 100 mg ORAL ANDA 12 sections
Benzonatate HUMAN PRESCRIPTION DRUG LABEL 1 16590-031 CAPSULE 100 mg ORAL ANDA 11 sections
benzonatate HUMAN PRESCRIPTION DRUG LABEL 1 21695-191 CAPSULE 100 mg ORAL ANDA 16 sections
benzonatate HUMAN PRESCRIPTION DRUG LABEL 1 21695-760 CAPSULE 200 mg ORAL ANDA 16 sections
Benzonatate HUMAN PRESCRIPTION DRUG LABEL 1 23155-898 CAPSULE, LIQUID FILLED 100 mg ORAL ANDA 12 sections
Benzonatate HUMAN PRESCRIPTION DRUG LABEL 1 23155-899 CAPSULE, LIQUID FILLED 200 mg ORAL ANDA 12 sections
Benzonatate 100 mg Human Prescription Drug Label 1 25000-002 CAPSULE, LIQUID FILLED 100 mg ORAL ANDA 16 sections
Benzonatate 200 mg Human Prescription Drug Label 1 25000-003 CAPSULE, LIQUID FILLED 200 mg ORAL ANDA 16 sections
Benzonatate HUMAN PRESCRIPTION DRUG LABEL 1 31722-956 CAPSULE 100 mg ORAL ANDA 11 sections
Benzonatate HUMAN PRESCRIPTION DRUG LABEL 1 31722-957 CAPSULE 150 mg ORAL ANDA 11 sections
Benzonatate HUMAN PRESCRIPTION DRUG LABEL 1 31722-958 CAPSULE 200 mg ORAL ANDA 11 sections
benzonatate HUMAN PRESCRIPTION DRUG LABEL 1 33261-147 CAPSULE 100 mg ORAL ANDA 16 sections
benzonatate HUMAN PRESCRIPTION DRUG LABEL 1 33261-634 CAPSULE 200 mg ORAL ANDA 16 sections
Benzonatate HUMAN PRESCRIPTION DRUG LABEL 1 42254-078 CAPSULE, LIQUID FILLED 100 mg ORAL ANDA 10 sections
Benzonatate HUMAN PRESCRIPTION DRUG LABEL 1 42291-091 CAPSULE 100 mg ORAL ANDA 15 sections
Benzonatate HUMAN PRESCRIPTION DRUG LABEL 1 42291-092 CAPSULE 200 mg ORAL ANDA 15 sections